H-Index & Metrics Best Publications

H-Index & Metrics

Discipline name H-index Citations Publications World Ranking National Ranking
Immunology D-index 47 Citations 7,717 86 World Ranking 3021 National Ranking 1430

Overview

What is he best known for?

The fields of study he is best known for:

  • Antibody
  • Immune system
  • Virus

His primary scientific interests are in Immunology, Immunogenicity, Antibody, Virology and Immune system. As part of his studies on Immunology, he frequently links adjacent subjects like Receptor. His Receptor study also includes

  • Inflammation together with Cell surface receptor,
  • Biochemistry most often made with reference to C3-convertase.

His Immunogenicity research includes themes of Hemagglutination Inhibition Tests, Adjuvant, Microbiology and Viruslike particle. His studies deal with areas such as Guinea pig, Pharmacology and Glycoprotein as well as Antibody. His Immunoglobulin G study in the realm of Immune system connects with subjects such as Heterologous.

His most cited work include:

  • The role of complement in inflammation and phagocytosis (426 citations)
  • Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. (265 citations)
  • Safety and Immunogenicity of 26-Valent Group A Streptococcus Vaccine in Healthy Adult Volunteers (249 citations)

What are the main themes of his work throughout his whole career to date?

Louis Fries spends much of his time researching Immunology, Virology, Immunogenicity, Antibody and Vaccination. His study on Immunology is mostly dedicated to connecting different topics, such as Adverse effect. His Immunity research extends to Virology, which is thematically connected.

The Immunogenicity study combines topics in areas such as Titer, Influenza vaccine, Immunization, Adjuvant and Seroconversion. He combines subjects such as Receptor, Guinea pig and Microbiology with his study of Antibody. His study in Vaccination is interdisciplinary in nature, drawing from both Internal medicine and Malaria.

He most often published in these fields:

  • Immunology (54.72%)
  • Virology (38.68%)
  • Immunogenicity (36.79%)

What were the highlights of his more recent work (between 2016-2021)?

  • Virology (38.68%)
  • Adjuvant (21.70%)
  • Immunogenicity (36.79%)

In recent papers he was focusing on the following fields of study:

Louis Fries mainly focuses on Virology, Adjuvant, Immunogenicity, Vaccination and Antibody. His Virology study integrates concerns from other disciplines, such as Receptor, Immune system and Glycoprotein. The study incorporates disciplines such as Spleen, Plasmodium falciparum and Vaccine efficacy in addition to Adjuvant.

Vaccination is a primary field of his research addressed under Immunology. His study connects Cardiopulmonary disease and Immunology. His Antibody study combines topics in areas such as Virus and Influenza vaccine.

Between 2016 and 2021, his most popular works were:

  • Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. (265 citations)
  • A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age (54 citations)
  • SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 elicits immunogenicity in baboons and protection in mice (52 citations)

In his most recent research, the most cited papers focused on:

  • Antibody
  • Virus
  • Immune system

The scientist’s investigation covers issues in Immunogenicity, Virology, Antibody, Virus and Adjuvant. His Immunogenicity study is related to the wider topic of Immunology. His work in the fields of Immunology, such as Immunization, Respiratory syncytial virus and Vaccination, overlaps with other areas such as Placebo.

While the research belongs to areas of Virology, Louis Fries spends his time largely on the problem of Glycoprotein, intersecting his research to questions surrounding Synthetic immunology, 2019-20 coronavirus outbreak and Cytotoxic T cell. His research integrates issues of Respiratory tract infections, Lower respiratory tract infection, Respiratory system, Disease and Pediatrics in his study of Virus. The study incorporates disciplines such as Spleen and Receptor in addition to Adjuvant.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

The role of complement in inflammation and phagocytosis

Michael M Frank;Louis F Fries.
Immunology Today (1991)

657 Citations

Plasma fibronectin enhances phagocytosis of opsonized particles by human peripheral blood monocytes.

C G Pommier;S Inada;L F Fries;T Takahashi.
Journal of Experimental Medicine (1983)

354 Citations

Safety and Immunogenicity of 26-Valent Group A Streptococcus Vaccine in Healthy Adult Volunteers

Shelly A. McNeil;Scott A. Halperin;Joanne M. Langley;Bruce Smith.
Clinical Infectious Diseases (2005)

349 Citations

Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy

Louis F. Fries;Daniel M. Gordon;Roberta L. Richards;James E. Egan.
Proceedings of the National Academy of Sciences of the United States of America (1992)

328 Citations

Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine.

Cheryl Keech;Gary Albert;Iksung Cho;Andreana Robertson.
The New England Journal of Medicine (2020)

305 Citations

Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model.

Milan Basta;Paul Kirshbom;Michael M. Frank;Louis F. Fries.
Journal of Clinical Investigation (1989)

236 Citations

Glycoprotein C of herpes simplex virus 1 is an inhibitor of the complement cascade.

L F Fries;H M Friedman;G H Cohen;R J Eisenberg.
Journal of Immunology (1986)

215 Citations

A Recombinant Viruslike Particle Influenza A (H7N9) Vaccine

Louis F. Fries;Gale E. Smith;Gregory M. Glenn.
The New England Journal of Medicine (2013)

199 Citations

Complement component C3b binds directly to purified glycoprotein C of herpes simplex virus types 1 and 2.

Roselyn J. Eisenberg;Manuel Ponce de Leon;Harvey M. Friedman;Louis F. Fries.
Microbial Pathogenesis (1987)

179 Citations

C3b covalently bound to IgG demonstrates a reduced rate of inactivation by factors H and I.

Louis F. Fries;Thelma A. Gaither;Carl H. Hammer;Michael M. Frank.
Journal of Experimental Medicine (1984)

172 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing L F Fries

Carl R. Alving

Carl R. Alving

Walter Reed Army Institute of Research

Publications: 46

James B. Dale

James B. Dale

University of Tennessee Health Science Center

Publications: 38

Gary H. Cohen

Gary H. Cohen

University of Pennsylvania

Publications: 37

Harvey M. Friedman

Harvey M. Friedman

University of Pennsylvania

Publications: 36

Roselyn J. Eisenberg

Roselyn J. Eisenberg

University of Pennsylvania

Publications: 35

Yoshihiro Kawaoka

Yoshihiro Kawaoka

University of Tokyo

Publications: 29

Bruce L. Innis

Bruce L. Innis

GlaxoSmithKline (United Kingdom)

Publications: 28

Stephen L. Hoffman

Stephen L. Hoffman

Sanaria

Publications: 27

Michael F. Good

Michael F. Good

Griffith University

Publications: 25

Florian Krammer

Florian Krammer

Icahn School of Medicine at Mount Sinai

Publications: 25

Michel D. Kazatchkine

Michel D. Kazatchkine

Sorbonne University

Publications: 24

Michael M. Frank

Michael M. Frank

Duke University

Publications: 24

Kanta Subbarao

Kanta Subbarao

University of Melbourne

Publications: 23

John D. Lambris

John D. Lambris

University of Pennsylvania

Publications: 22

Barney S. Graham

Barney S. Graham

National Institutes of Health

Publications: 21

Jonathan R. Carapetis

Jonathan R. Carapetis

University of Western Australia

Publications: 21

Something went wrong. Please try again later.